Cell MedX Corp (OTCMKTS:CMXC) Broadening The Focus

1149

Cell MedX Corp (OTCMKTS:CMXC) discovery Phase study performed a couple of years ago revealed that its eBalance Technology augmented insulin sensitivity and regulated glycolytic procedures leading in improved transport and use of glucose during a single therapy. With the diabetes devices industry projected to hit $35.5 billion by 2024, a permitted offering that enhances insulin sensitivity could turn out to be a blockbuster therapeutic device.

The buzz

Since then, further probes led the firm to extend its focus to include ailments like high blood pressure and Parkinson’s disease, where Cell MedX considers micro current technology could show useful. GBI Research anticipates Parkinson’s disease to become a $3.2 billion market in next 4 years, while Technavio projects hypertension drugs to record sales of over $32 billion by 2020. These are notable additional end markets for the firm’s breakthrough technology.

Cell MedX’s short-term objective is to get nod for the eBalance technology to address general wellness and treat pain. It intends to preliminary deploy pain management solutions using qualified supervisory protocols, with premium therapies for associated ailments to be provided by clinicians. Later team would apply to market and issue the device to cure a variety of other ailments including Parkinson’s disease and diabetes on an individualized basis, retaining appropriate supervisory procedures, while potentially associating with research institutions to further advance areas of investigation into different areas where the technology has demonstrated potential for future use.

Cell MedX’s eBalance Pro is grounded on a fully software-supported microcurrent technology. Utilizing cutting-edge software, it identifies certain frequencies for microcurrent app through the application of a bio-feedback algorithm that notes and delivers tailored frequencies to offer optimal outcomes which resolve specific, and in most cases, painful conditions.

Upon the completion of the imminent clinical studies, the eBalance Pro will be the sole microcurrent therapy advanced to treat specific medical ailments on an individualized basis.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.